SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Fabrazyme

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2003.
Why 3/10
Fabrazyme is an already-approved, marketed drug with no pending PDUFA date, pivotal readout, or label-expansion decision in the next 12 months. It contributes roughly 0.6% of Sanofi's total revenue, so even a supply disruption or biosimilar entry would not be a material binary catalyst for SNY stock. Per the rubric, an approved drug with no upcoming regulatory decision scores 3-5; the low end reflects the drug's small weight within Sanofi's diversified portfolio.
Actionable Insight NEUTRAL

Fabrazyme has no upcoming PDUFA date, pivotal readout, or label-expansion decision in the next 12 months. Watch for resolution of the FDA Warning Letter at the Waterford plant (which could affect supply continuity) and for biosimilar entry in major markets. Neither is a hard binary catalyst for Sanofi's stock given the drug's small revenue contribution.

Price Chart

Loading chart...

Executive Summary

Fabrazyme (agalsidase beta) is Sanofi's enzyme replacement therapy for Fabry disease, first approved by the FDA in April 2003 and now the #1 prescribed treatment for patients aged 2 and older. It generated roughly EUR 252 million in 2025 sales, a small fraction of Sanofi's EUR 43.6 billion total revenue. The drug faces near-term headwinds from an FDA Warning Letter (June 2026) at its Waterford, Ireland manufacturing plant that triggered supply disruptions, though the EMA has since listed the shortage as resolved. Biosimilar competition is emerging in Latin America (Biosidus' Agalzyme) and other regions. As a mature, approved product with no pending regulatory catalyst, Fabrazyme is not a material binary driver for Sanofi's stock.

How It Works

Fabrazyme is an enzyme replacement therapy (ERT) for Fabry disease, a rare genetic disorder where patients lack a working version of an enzyme called alpha-galactosidase A. Without this enzyme, fatty substances build up in cells and damage organs. Fabrazyme supplies a lab-made version of the missing enzyme, which is taken up by cells to clear the buildup and slow disease progression. It is given as an intravenous infusion.

Trial Status

Fabrazyme was approved by the FDA in April 2003 based on a randomized, double-blind, placebo-controlled trial in 58 Fabry patients. It has since accumulated over 20 years of real-world clinical experience. The label was expanded to include pediatric patients aged 2 years and older. No new pivotal trials are ongoing for this molecule.

The Two-Sided Case

▲ Bull Case3
Fabrazyme remains the #1 prescribed FDA-approved treatment for Fabry disease, with over 20 years of real-world data supporting its safety and efficacy across all ages (2+), genders, and disease severities.
The EMA has listed the Fabrazyme supply shortage as resolved, suggesting manufacturing disruptions may be stabilizing.
Sanofi's total revenue reached EUR 43.6 billion in 2025 with 9.9% growth, and the broader rare-disease portfolio provides diversification against any single product issue.
▼ Bear Case3
The FDA issued a Warning Letter (June 22, 2026) to Sanofi's Genzyme Ireland Waterford facility citing data integrity violations and CGMP failures, which led to supply disruptions for Fabrazyme and could lead to further regulatory action or remediation costs.
Biosimilar competition is emerging: Laboratorio Biosidus launched Agalzyme (agalsidase beta biosimilar) in Argentina and Latin America in 2025, and other biosimilars (GNR-062, AGABIO) are in development, potentially eroding Fabrazyme's market share over time.
Fabrazyme generated only ~EUR 252 million in 2025 (roughly 0.6% of Sanofi's total revenue), making it a minor product that could face margin pressure from biosimilars without meaningfully impacting Sanofi's overall financials in either direction.

Upcoming Catalysts

  • Resolution or escalation of the FDA Warning Letter at Sanofi's Waterford, Ireland manufacturing plant
  • Biosimilar market entry in additional regions beyond Latin America

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 10

Hover a chip for the title
1 accessdata.fda.gov2 fda.gov3 ema.europa.eu4 mpssociety.org.uk5 pmarketresearch.com6 sanofimarketaccess.com7 fabrydiseasenews.com8 sanofi.com9 stockanalysis.com10 assets.publishing.service.gov.uk